In today’s session Alkermes Plc (ALKS) recorded an unusually high (288) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious ALKS decrease. With 288 contracts traded and 8444 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: ALKS161216P00050000 closed last at: $0.35 or 50% down. About 63,144 shares traded hands. Alkermes Plc (NASDAQ:ALKS) has risen 41.15% since April 20, 2016 and is uptrending. It has outperformed by 36.60% the S&P500.
Alkermes Plc (NASDAQ:ALKS) Ratings Coverage
Out of 8 analysts covering Alkermes (NASDAQ:ALKS), 6 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 75% are positive. Alkermes has been the topic of 16 analyst reports since September 1, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by Leerink Swann given on Friday, October 21. The firm earned “Neutral” rating on Friday, January 22 by UBS. JP Morgan upgraded Alkermes Plc (NASDAQ:ALKS) on Friday, October 21 to “Overweight” rating. Cowen & Co upgraded Alkermes Plc (NASDAQ:ALKS) on Tuesday, July 26 to “Market Perform” rating. The firm has “Outperform” rating given on Thursday, January 21 by Leerink Swann. Jefferies maintained it with “Buy” rating and $70 target price in Friday, October 21 report. On Thursday, May 26 the stock rating was initiated by Evercore with “Buy”. The stock of Alkermes Plc (NASDAQ:ALKS) earned “Buy” rating by Jefferies on Friday, July 29. The rating was maintained by Barclays Capital with “Overweight” on Wednesday, July 13. Morgan Stanley upgraded Alkermes Plc (NASDAQ:ALKS) rating on Tuesday, September 1. Morgan Stanley has “Overweight” rating and $85 price target.
According to Zacks Investment Research, “Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes’ pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.”
Insitutional Activity: The institutional sentiment increased to 1.2 in 2016 Q2. Its up 0.24, from 0.96 in 2016Q1. The ratio increased, as 31 funds sold all Alkermes Plc shares owned while 75 reduced positions. 34 funds bought stakes while 68 increased positions. They now own 135.77 million shares or 0.84% less from 136.92 million shares in 2016Q1.
Tfs Ltd Liability Corporation holds 0.07% or 8,748 shares in its portfolio. Moreover, Us Bancorporation De has 0% invested in Alkermes Plc (NASDAQ:ALKS) for 531 shares. Grp Inc One Trading Lp owns 1,532 shares or 0% of their US portfolio. Dimensional Fund Advsrs Lp reported 169,266 shares or 0% of all its holdings. Point72 Asia (Hong Kong) Ltd holds 20,252 shares or 1.01% of its portfolio. Waddell & Reed Inc accumulated 0.18% or 1.98 million shares. Bb&T holds 0.01% or 10,199 shares in its portfolio. Orbimed Ltd Liability accumulated 0.08% or 172,000 shares. Henderson Gp Plc reported 14,789 shares or 0.01% of all its holdings. Fiera Cap Corporation owns 6,400 shares or 0% of their US portfolio. Moreover, Teachers Retirement Systems Of The State Of Kentucky has 0.07% invested in Alkermes Plc (NASDAQ:ALKS) for 124,620 shares. State Street Corporation holds 3.68M shares or 0.02% of its portfolio. Capstone Asset has 0.01% invested in the company for 6,285 shares. Bankshares Of Montreal Can has invested 0.01% of its portfolio in Alkermes Plc (NASDAQ:ALKS). Twin Focus Cap Partners Ltd Liability Company owns 40,000 shares or 1.37% of their US portfolio.
Alkermes Public Limited Company is a biopharmaceutical company. The company has a market cap of $8.85 billion. The Firm is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It currently has negative earnings. The Firm has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system disorders, such as schizophrenia, depression, addiction and multiple sclerosis.
ALKS Company Profile
Alkermes Public Limited Company, incorporated on May 4, 2011, is a biopharmaceutical company. The Firm is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Firm has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. The Company’s products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. The Company’s product platforms include injectable extended release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.
More recent Alkermes Plc (NASDAQ:ALKS) news were published by: Fool.com which released: “Why Alkermes PLC Skyrocketed Today” on October 21, 2016. Also Fool.com published the news titled: “Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward” on November 07, 2016. Businesswire.com‘s news article titled: “Alkermes plc Reports Third Quarter 2016 Financial Results” with publication date: November 02, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.